Talc Powder and Ovarian Cancer

Ovarian Cancer

The term “ovarian cancer” includes various cancer subtypes. The various forms (or subtypes) of ovarian cancer are identified by their locations on the ovary and distinguishable by their different characteristics (expressions). Approximately 90% of all ovarian cancers are found in the epithelium.

Gynecological Anatomy related to Ovarian Cancer

The Epithelium

Most ovarian cancer is found in the epithelium, which is the layer of tissue that surrounds (encapsulates) the ovary. Collectively, these are referred to as epithelial ovarian cancers. There are various subtypes of epithelial ovarian cancers including serous cell and endometrioid (endometrial).

The Peritoneum

The peritoneum is bodily tissue that is separate and distinct from the ovaries. It is a membrane that surrounds, protects and helps support the abdominal organs including all of the female reproductive organs. The location of the peritoneum identifies another subtype of ovarian cancer referred to as “peritoneal ovarian cancer.” A small percentage (~10%) of ovarian cancer cases originate in the peritoneum.

Subtypes of Ovarian Cancer

Peritoneal Ovarian Cancers

Peritoneal ovarian cancer originates outside of the ovaries, in one or more areas of the peritoneum tissue- a membrane that surrounds, protects and helps support the abdominal organs including, for women, the uterus and all of the other female reproductive organs. Primary peritoneal ovarian cancer can spread to other locations in the abdomen including, in some cases, the ovaries. The peritoneum consists of epithelial cells and, in this way, is similar to the epithelium tissue that encapsulates the ovaries. Due to this similarity, treatment of epithelial and peritoneal cancers is often similar.

However, peritoneal cancer can be confined to the peritoneum and not affect the ovaries. It can develop in women who have had their ovaries removed. “Primary” peritoneal cancer can occur anywhere in the peritoneum and not implicate the ovaries. In other cases, peritoneal cancer cells can be present in both the peritoneum and one or both ovaries.

The serous cell lining (outer surface) of the ovaries and the serous cell composition of the peritoneum interact which enables cancer cells to migrate between the two anatomical structures. When cancer cells are present in both the ovary(ies) and the peritoneum, the diagnosis is peritoneal ovarian cancer.

Epithelial Ovarian Cancers

The most common types of ovarian cancer are the referred to collectively as the epithelial cancers, all of which are found in the epithelium - the layer of tissue that surrounds the ovary. Epithelial Ovarian include the following subtypes:

Serous cell epithelial ovarian cancer
This is the most common subtype of all epithelial ovarian cancer, accounting for approximately 60% of newly diagnosed cases of ovarian cancer. When diagnosed, serous cell epithelial ovarian cancer is commonly classified as either low-grade or high-grade depending upon the nuclei and mitotic characteristics of the cells.
Endometrioid (endometrial) ovarian cancer
This subtype is identified by its relationship to the endometrium, which is the membrane that is the interior lining of the uterus. Endometrioid (endometrial) ovarian cancer can often develop in conjunction with other cancers or diseases or abnormalities affecting the endometrium such as endometriosis
Mucinous, Clear Cell and Unclassified/Undifferentiated
These three are less common (rare) subtypes of ovarian cancer. Though distinguishable for diagnostic purposes, the prescribed treatment for each is similar.

Ovarian Cancer Staging

Staging of cancer provides doctors with diagnostic information that helps guide consideration of treatment options. Staging protocol generally accounts for the severity of the cancer diagnosis. The first step is diagnosis of the ovarian cancer subtype - serous cell, endometrioid (endometrial), peritoneal, etc. Then next step is “staging” to understand its severity and help narrow potential treatment options.

The National Ovarian Cancer Coalition (NOCC)

NOCC provides the following staging protocol that guides doctors and patients:

Stage I

Stage I
Growth of the cancer is limited to the ovary or ovaries.
Stage IA
Growth is limited to one ovary and the tumor is confined to the inside of the ovary. There is no cancer on the outer surface of the ovary. There are no ascites present containing malignant cells. The capsule is intact.
Stage IB
Growth is limited to both ovaries without any tumor on their outer surfaces. There are no ascites present containing malignant cells. The capsule is intact.
Stage IC
The tumor is classified as either Stage IA or IB and one or more of the following are present: (1) tumor is present on the outer surface of one or both ovaries; (2) the capsule has ruptured; and (3) there are ascites containing malignant cells or with positive peritoneal washings.

Stage II

Stage II
Growth of the cancer involves one or both ovaries with pelvic extension.
Stage IIA
The cancer has extended to and/or involves the uterus or the fallopian tubes, or both.
Stage IIB
The cancer has extended to other pelvic organs.
Stage IIC
The tumor is classified as either Stage IIA or IIB and one or more of the following are present: (1) tumor is present on the outer surface of one or both ovaries; (2) the capsule has ruptured; and (3) there are ascites containing malignant cells or with positive peritoneal washings.

Stage III

Stage III
Growth of the cancer involves one or both ovaries, and one or both of the following are present: (1) the cancer has spread beyond the pelvis to the lining of the abdomen; and (2) the cancer has spread to lymph nodes. The tumor is limited to the true pelvis but with histologically proven malignant extension to the small bowel or omentum.
Stage IIIA
During the staging operation, the practitioner can see cancer involving one or both of the ovaries, but no cancer is grossly visible in the abdomen and it has not spread to lymph nodes. However, when biopsies are checked under a microscope, very small deposits of cancer are found in the abdominal peritoneal surfaces.
Stage IIIB
The tumor is in one or both ovaries, and deposits of cancer are present in the abdomen that are large enough for the surgeon to see but not exceeding 2 cm in diameter. The cancer has not spread to the lymph nodes.
Stage IIIC
The tumor is in one or both ovaries, and one or both of the following is present: (1) the cancer has spread to lymph nodes; and/or (2) the deposits of cancer exceed 2 cm in diameter and are found in the abdomen.

Stage IV

Stage IV
This is the most advanced stage of ovarian cancer. Growth of the cancer involves one or both ovaries and distant metastases (spread of the cancer to organs located outside of the peritoneal cavity) have occurred. Finding ovarian cancer cells in pleural fluid (from the cavity which surrounds the lungs) is also evidence of stage IV disease.

Source: National Ovarian Cancer Coalition (NOCC)

Free Guide on Talc and Ovarian Cancer

Please fill in the form to request a FREE GUIDE for more information about the link between ovarian cancer and long term talc powder use.

*
*
*
*
*
Have you or a loved one been diagnosed with ovarian cancer after January 1, 2010 and after long term use of talc-based baby or body powders? *
 All personal information will be kept private.
Cramer DW et al. The Association Between Talc Use and Ovarian Cancer: A Retrospective Case-Control Study in Two US States. Epidemiology. 2016 May; 27(3):334-46. http://www.ncbi.nlm.nih.gov/pubmed/26689397
Gertig DM et al. Prospective Study of Talc Use and Ovarian Cancer. J Natl Cancer Inst. 2000; 92:249–52. http://jnci.oxfordjournals.org/content/92/3/249.full
Terry KL et al. Genital powder use and risk of ovarian cancer: A pooled analysis of 8,525 cases and 9,859 controls. Cancer Prev Res (Phila). 2013; 6:811–821. http://cancerpreventionresearch.aacrjournals.org/content/6/8/811
Cramer DW. Ovarian cancer and talc: a case-control study. Cancer. 1982; 50:372-376. http://www.ncbi.nlm.nih.gov/pubmed/7083145
Henderson WJ. Talc and Carcinoma of the Ovary and Cervix. BJOG: An International Journal of Obstetrics & Gynaecology. 1971; 78:266-272. http://onlinelibrary.wiley.com/doi/10.1111/j.1471-0528.1971.tb00267.x/abstract
American Cancer Society. Talcum Powder and Cancer. Last medical review: November 17, 2014. http://www.cancer.org/cancer/cancercauses/othercarcinogens/athome/talcum-powder-and-cancer
National Ovarian Cancer Coalition (NOCC). http://www.ovarian.org/types_and_stages.php
Johnson & Johnson Talcum Powder Litigation http://www.njd.uscourts.gov/johnson-johnson-talcum-powder-litigation
“Johnson & Johnson Knew for Decades that asbestos lurked in its Baby Powder” A Reuters Investigation by Lisa Girion, Reuters News, December 14, 2018. https://www.reuters.com/investigates/special-report/johnsonandjohnson-cancer/
Grens K. Can Talc Cause Cancer? The Scientist. March 2, 2016. http://www.the-scientist.com/?articles.view/articleNo/45493/title/Can-Talc-Cause-Cancer-/
Cohen R. Genital talc boosts ovarian cancer risk in study. Reuters. March 3, 2016. http://www.reuters.com/article/us-health-talc-cancer-idUSKCN0W52R1
Berfield S et al. Johnson & Johnson Has a Baby Powder Problem: More than 1,000 women are suing the company for covering up a cancer risk. Bloomberg Businessweek. March 31, 2016. http://www.bloomberg.com/features/2016-baby-powder-cancer-lawsuits/
Bross T et al. J&J Must Pay $72 Million Over Talc Tied to Woman's Cancer. Bloomberg. February 22-23, 2016. http://www.bloomberg.com/news/articles/2016-02-23/j-j-ordered-to-pay-72-million-over-talc-tied-to-ovarian-cancer
Feeley J et al. J&J's Talcum Powder Goes on Trial in Ovarian Cancer Lawsuits. Bloomberg. February 2, 2016. http://www.bloomberg.com/news/articles/2016-02-02/j-j-s-talcum-powder-goes-on-trial-in-ovarian-cancer-lawsuits
Mulcahy N. Talc Powder, Ovarian Cancer Link: What is the Evidence? Medscape Medical News/Oncology. February 25, 2016. http://www.medscape.com/viewarticle/859485
International Agency for Research on Cancer http://www.who.int/about/iarc/en/
“In Battle Over Johnson’s Baby Powder, Asbestos Opens a New Legal Front” by Roni Caryn Rabin and Tiffany Hsu, New York Times, December 14, 2018. https://www.nytimes.com/2018/12/14/business/baby-powder-asbestos-johnson-johnson.html

Disclaimer: Submission of information does not establish an attorney-client relationship and should not be viewed or understood as doing so.